Intuitive Surgical Is the Robotic-Assisted Surgery Leader, but Medtronic Is Making Moves. Here's What Investors Need to Know.

There is a lot to like about Intuitive Surgical (NASDAQ: ISRG) and one very notable thing to dislike. And once you see the problem, you'll instantly understand why medical device competitor Medtronic (NYSE: MDT) could be a more attractive investment option. But the real story here is about what's yet to come for Medtronic.Here's what you need to know.There is absolutely nothing wrong with Intuitive Surgical's business. In fact, the da Vinci surgical robot is industry-leading technology. And it is still selling well, with 427 new systems put in place in the third quarter of 2025, up from 379 in the same quarter of 2024. That brings the total number of da Vinci systems to 10,763. Worldwide, there were 20% more procedures handled by this medical device maker's surgical robots year over year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool